【Abstract】 Objective To observe the clinical efficacy of ubenimex capsule combined with chemotherapy in the treatment of advanced lung cancer. Methods 60 patients with advanced nonsmall cell lung cancer (NSCLC) treated in our hospital from February 2015 to October 2016 were divided into control group and observation group with 30 cases in each group according to the random number table method. The control group was given the paclitaxel and cisplatin (TP) program regimen, and the observation group was given the ubenimex capsule combined with TP regimen. The levels of immune function［T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+), the proportion of NK cells］, quality of life core scale (QLQC30) score, the adverse reactions, shortterm efficacy, progression free survival (PFS) were compared between the 2 groups. Results There was no significant difference in the overall response rate (RR), disease control rate (DCR), PFS (P＞005). The level of CD8+ in the observation group after treatment was significantly lower than that in the control group (P<005), and the levels of CD3+, CD4+, CD4+/CD8+ and the proportion of NK cells were significantly higher than those in the control group (P<005). The every items scores of the QLQC30 scale in the observation group were significantly better or higher than those in the control group (P<005), and the reduction rate of III ~ IV grade leukocyte was significantly lower than that in the control group (P<005), and there was no significant difference in the other adverse reactions (P＞005). Conclusion Compared with the single use of chemotherapy, the ubenimex capsule combined with chemotherapy for advanced NSCLC can improve the body immune function, and improve the quality of life and reduce the adverse reactions of chemotherapy.